Image Credit: Agilent
Agilent Technologies Inc. has signed a Memorandum of Understanding (MoU) with Ubix Therapeutics to accelerate highly targeted cancer therapy research and development in South Korea over the next five years.
Under this agreement, the two companies will conduct joint research to develop targeted protein degradation (TPD) and antibody-drug conjugate (ADC). This collaboration will combine Ubix’s proprietary Degraducer anti-cancer drugs platform which features novel E3 ligase binders with Agilent’s cancer research and technology capabilities.
Small molecule-induced TPD and ADC are rapidly emerging as a promising approach in precision oncology across the pharma and biopharma industries, with the global TPD market size estimated to reach $4.37 billion by 2034. This novel method invites therapeutic potential in previously undruggable molecular spaces, paving the way to deliver safer and more effective answers for even the most difficult targets in ubiquitin proteasome pathway (UPP) and ligase complex.
The collaboration leverages Agilent’s innovative technologies, such as InfinityLab Bio LC portfolio, LC/MS systems, and BioTek product families, developing efficient analytical methods and workflows to advance targeted cancer therapy and immuno-oncology research. This work supports Ubix in addressing the unmet needs of patients and increasing access to innovative novel treatments that may improve patient outcomes.
